CAPR Earnings & Financial Statements
Capricor Therapeutics, Inc.
$7.85
-$0.16(-2.01%)
39
Overall
60
Value
10
Tech
47
Quality
Market Cap
$465.69M
Volume
922.98K
52W Range
$2.96 - $40.37
Target Price
$23.67
CAPR earnings and financial statements: Capricor Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CAPR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $22.27M | $25.18M | $2.55M | $244.9K |
| Operating income | -$108.14M | -$42.56M | -$24.08M | -$29.70M | -$20.94M |
| EBITDA | -$100.11M | -$39.04M | -$21.22M | -$29.16M | -$20.69M |
| Net income | -$105.04M | -$40.47M | -$22.29M | -$29.02M | -$20.02M |
| EPS (diluted) | $-2.26 | $-1.15 | $-0.83 | $-1.18 | $-0.87 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $355.95M | $170.48M | $58.73M | $50.09M | $41.33M |
| Total liabilities | $50.16M | $25.02M | $36.13M | $38.31M | $9.96M |
| Shareholders’ equity | $305.79M | $145.46M | $22.60M | $11.79M | $31.37M |
| Cash and equivalents | $287.85M | $11.29M | $14.69M | $9.60M | $34.89M |
| Long-term debt | $14.32M | $616.3K | $1.49M | $5.25M | $5.83M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$69.81M | -$40.00M | -$25.60M | $4.92M | -$16.81M |
| Capital expenditure | -$2.90M | -$1.17M | -$2.05M | -$3.36M | -$1.20M |
| Free cash flow | -$72.72M | -$41.16M | -$27.64M | $1.56M | -$18.01M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CAPR | $7.85 | -2.0% | 922.98K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Capricor Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW